C-Terminal Deletions in the ALAS2 Gene Lead to Gain of Function and Cause X-linked Dominant Protoporphyria without Anemia or Iron Overload  by Whatley, Sharon D. et al.
REPORT
C-Terminal Deletions in the ALAS2 Gene Lead
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Protoporphyria without Anemia or Iron Overload
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Carole Beaumont,3 Michael N. Badminton,1 George H. Elder,1 S. Alexander Holme,5 Alexander
V. Anstey,5 Michelle Parker,6 Anne V. Corrigall,6 Peter N. Meissner,6 Richard J. Hift,6 Joanne
T. Marsden,7 Yun Ma,8 Giorgina Mieli-Vergani,8 Jean-Charles Deybach,2,3,* and Herve´ Puy2,3
All reportedmutations inALAS2, which encodes the rate-regulating enzyme of erythroid heme biosynthesis, cause X-linked sideroblastic
anemia. We describe eight families with ALAS2 deletions, either c.1706-1709 delAGTG (p.E569GfsX24) or c.1699-1700 delAT
(p.M567EfsX2), resulting in frameshifts that lead to replacement or deletion of the 19–20 C-terminal residues of the enzyme. Prokaryotic
expression studies show that both mutations markedly increase ALAS2 activity. These gain-of-function mutations cause a previously
unrecognized form of porphyria, X-linked dominant protoporphyria, characterized biochemically by a high proportion of zinc-proto-
porphyrin in erythrocytes, in which a mismatch between protoporphyrin production and the heme requirement of differentiating
erythroid cells leads to overproduction of protoporphyrin in amounts sufﬁcient to cause photosensitivity and liver disease.Each of the seven inherited porphyrias results froma partial
deﬁciency of an enzyme of heme biosynthesis. Mutations
that cause porphyria have been identiﬁed in all the genes
of the heme biosynthetic pathway except ALAS1 and
ALAS2, which encode the ubiquitously expressed
(ALAS1) and erythroid-speciﬁc (ALAS2) isoforms of mito-
chondrial 5-aminolevulinate synthase (ALAS) (EC
2.3.1.37), the initial, rate-regulating enzyme of the path-
way.1 ALAS2 is essential for hemoglobin formation by ery-
throid cells, and ALAS1 cannot replace this function. No
mutations have been identiﬁed in ALAS1, but pathogenic
mutations in the 14.4 kb, 11-exon-containing ALAS2 cause
X-linked hereditary sideroblastic anemia (XLSA [MIM
301300]) with iron overload.2
Erythropoietic protoporphyria (EPP [MIM 177000]) is an
inherited disorder caused by partial mitochondrial deﬁ-
ciency of ferrochelatase (FECH) (EC 4.99.1.1), the terminal
enzyme of heme biosynthesis. Accumulation of protopor-
phyrin IX in erythrocytes and other tissues leads to lifelong
photosensitivity and, in about 2% of patients, severe liver
disease.3 Most patients have autosomal-dominant EPP
(dEPP), in which clinical expression normally requires co-
inheritance of an FECH mutation that abolishes or mark-
edly reduces FECH activity trans to a hypomorphic FECH
IVS3-48C allele carried by about 11% of western Euro-
peans.4 About 4% of families have autosomal-recessive
EPP.4 However, mutational analysis fails to detect FECHmutations in about 7% of EPP families, of which about
3% are homozygous for the wild-type FECH IVS3-48T
allele,5 suggesting possible involvement of another locus.
Within this subgroup of families with mutation-nega-
tive EPP, we studied eight families in which at least one in-
dividual had acute photosensitivity clinically indistin-
guishable from that of dEPP. These families were
identiﬁed through referral to specialist porphyria centers
or during surveys of EPP in the UK6 or South Africa7 and
were of western European (four families), Jewish, north
African, Indo-Asian, or Sudanese (one family each) ances-
try. Our study was conducted in accord with the World
Medical Association Declaration of Helsinki ethical princi-
ples for medical research involving human subjects and its
subsequent amendments. All patients or their parents gave
informed consent to investigation. Prior ethical approval
was obtained for patient surveys.6,7
Genomic DNA was extracted from whole blood. For se-
quencing of ALAS2, FECH, and SLC25A37 (MIM 610387)
(GenBank accession numbers: human ALAS2
[NM000032.3], FECH [NM000140], and SLC25A37
[NM0166112] cDNAs and ALAS2 [NT011630] and
SLC25A37 [NT023666] genes), all exons and their ﬂanking
sequences were ampliﬁed by polymerase chain reaction
(PCR) (primers and conditions are available from the au-
thors). PCR-ampliﬁed double-stranded DNA was puriﬁed
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Table 1. Erythrocyte Porphyrins, Hematological Measurements, and Serum Iron Indices in Patients with X-Linked Dominant
Protoporphyria and Their Unaffected Relatives
XLDPP Unaffected Relatives
Male Female Male Female
Total protoporphyrin
(fold increase)
27, 11–103 (7) 24, 6–64 (16) Less than 1.0
Zinc protoporphyrin
(% total)
45, 19–58 (7) 46, 30–65 (15) Less than 80
Hemoglobin (g/dl) 14.3, 12.2–17.5 (5) 13.0, 12.4–14.1 (8) 14.2, 13.1–14.7 (8) 12.5, 11.9–14.2 (5)
MCV (fl) 87, 78–92 (13) 88, 84–96 (13)
Ferritin (mg/liter) 24, 10–104 (5)* 56, 21–154 (6) 102, 41–231 (8) 51, 33–91 (5)
Transferrin (g/liter) 2.87, 1.93–3.81 (9) 2.27, 1.59–2.84 (13)
Transferrin saturation (%) 16, 3–39 (11)* 26, 22–35 (13)
Transferrin receptor-1
(mg/liter)
1.44, 1.24–2.59 (10)** 1.16, 0.84–1.66 (13)
Measurements are medians and ranges. *p ¼ 0.02 versus unaffected male relatives; **p ¼ 0.04 versus unaffected relatives; differences between other
groups are not significant. Total porphyrin is expressed as n-fold increase (times upper limit of normal); for 17 patients with XLDPP in whom total eryth-
rocyte porphyrin was measured by the same method,8 the median concentration was 51.2 mmol/liter, range 20.1–195.6 mmol/liter (reference range: less
than 1.7 mmol/liter). Values in italics include male and female subjects.(QIAGEN, Cawley, UK) before being cycle sequenced with
ﬂuorescent ddNTPs (BigDye) and an ABI Prism 3130XL Ge-
netic Analyzer (PE Biosystems, Warrington, UK). We con-
ﬁrmed the presence or absence ofmutations by sequencing
both strands. Genotyping with FECH intragenic single-
nucleotide polymorphisms (SNPs),4 and microsatellite
markers for FECH7 and ALAS2 was performed on the ABI
PRISM 3100 automated sequencer. The ALAS2 microsatel-
lite markers (16AG at position 54992283, 17GT at position
55066050, and 23AC at position 55535957) were identiﬁed
at the UCSC genome bioinformatics site (Santa Cruz, CA;
see Web Resources). Results were analyzed with the ABI
PRISM GeneMapper software version 3.0. Erythrocyte por-
phyrins were measured as previously described.7,8 The per-
centage of zinc protoporphyrinwas calculated fromﬂoures-
cence emission spectra of ethanol8 or acetone9 extracts of
erythrocyte haemolystaes. FECH activity was measured as
described4 or indirectly from the amount of protoporphy-
rin formed from 5-aminolevulinate in the presence and
absence of Fe2þ.10 Differences between quantitative vari-
ables were assessed with theMann-Whitney test, and those
between proportions were assessed with Fisher’s exact test.
We differentiated patients in these eight families from
others with FECH mutation-negative EPP by showing
that the percentage of erythrocyte protoporphyrin present
as its zinc chelate (19%–65%, median 44%) was markedly
greater than in patients with dEPP (4%–13%, median
8%). Erythrocyte protoporphyrin concentrations were
also higher in our patients, in whom they were increased
24-fold (range: 6- to 103-fold) (Table 1) compared with
14-fold (range: 4- to 44-fold) in 171 patients with dEPP
(p < 0.001). In one patient with iron deﬁciency, erythro-
cyte protoporphyrin increased markedly (101-fold) but
then decreased as iron stores were replenished (Figure 1).
Lymphocyte FECH activity, measured in ten patients,
ranged from 74%–106% (median 85%) of the mean nor-
mal value, indicating that protoporphyrin accumulationThe Americanwas not caused by FECH deﬁciency resulting from a muta-
tion of the ubiquitously expressed FECH gene. We further
eliminated involvement of FECH by using intragenic
SNPs4 or microsatellite markers7 to show that protopor-
phyrin accumulation did not segregate with FECH haplo-
types in two families; other families were uninformative
or not tested. Because abnormal expression of mRNA for
mitoferrin has been implicated in the pathogenesis of
a similar form of protoporphyria (Shaw et al., Blood 108,
ASH Annual Meeting Abstracts, 6a), we sequenced all
exons of SLC25A37 and their ﬂanking sequences in all
eight probands but were unable to identify any disease-
speciﬁc mutation.
Parent-child transmission of overt disease is uncommon
in EPP.11 Our families were unusual in showing an appar-
ent dominant pattern of inheritance with an absence of
father-son transmission, which suggested X-linkage (Fig-
ure 2). We therefore investigated two candidate genes
that are located on the X chromosome and are involved
in heme formation, GATA1 (MIM 305371) (data not
shown) and ALAS2. Protoporphyrin accumulation segre-
gated with an X chromosome haplotype deﬁned by micro-
satellite markers around ALAS2 in three families (data not
shown). Sequencing of genomic DNA identiﬁed two differ-
ent deletions (c.1706–1709 delAGTG in six families;
c.1699–1700 delAT in two families) in ALAS2 exon 11, an
exon that is present in all ALAS2 transcripts.12 The frame-
shifts produced by these deletions lead to predicted alter-
ations of the 19–20 C-terminal amino acids of ALAS2 (Fig-
ures 3A and 3B); either deletion (delAT) or replacement by
a 23 residue sequence (delAGTG) that extends the enzyme
by 4 amino acids and alters the predicted secondary
structure (Supplemental Data; Figure 1). These mutations
segregated with photosensitivity (LOD score 7.8) and
were absent from 129 unrelated EPP patients (106
dEPP; 23 FECH-mutation-negative EPP) and 100 normal
chromosomes. The delAGTG mutation occurred on ﬁveJournal of Human Genetics 83, 408–414, September 12, 2008 409
different haplotypes, indicating that it has arisen on at
least ﬁve separate occasions, whereas the two delAT fami-
lies, both from southwest England, had the same back-
ground haplotype and may come from a single extended
family (data not shown). These ﬁndings show that these
deletions in ALAS2 cause a previously unrecognized X-
linked dominant protoporphyria (XLDPP) that, in contrast
to dEPP and other autosomal-dominant porphyrias,1 has
close to 100% penetrance (Figure 2).
All previously described mutations in ALAS2 have
caused XLSA (Human GeneMutation Database), including
a missense mutation (S568G) in the region lost or replaced
in our patients.13 Previously reported frameshift or other
Figure 2. Pedigrees of Eight Families
with FECH-Mutation-Negative Protopor-
phyria
Green circles and squares represent
patients with photosensitivity. Red circles
and squares represent patients with photo-
sensitivity and clinically overt liver
disease. Protoporphyric liver disease was
confirmed at autopsy or by needle biopsy
in all these patients except patient I1
(family H), for whom a diagnosis has not
been established. Patient II3 (family E)
has been reported previously.23 Clinical
information was not obtainable for pa-
tients C I, 3 and 4 or E I, 1 and 2.
Black dots within circles or squares
indicate individuals in whom either the
delAGTG (families A–E, H) or delAT (families
F and G) ALAS2 mutations were identified.
Crosses within circles or squares indicate individuals in whom sequencing excluded the presence of an ALAS2 mutation. The absence of
a black dot or cross indicates an individual from whom a DNA sample was not available for analysis. The LOD score for linkage between
photosensitivity and the ALAS2 mutation was calculated for families A–E.
Figure 1. Treating Iron Deficiency
Decreases Erythrocyte Protoporphyrin
Concentrations
Iron deficiency caused by bleeding from
a gastric ulcer was treated with omeprazole
and oral iron.
null ALAS2 mutations causing XLSA
have been embryonically lethal in
males.2 In our families, both sexes
were affected, and patients had nei-
ther anemia nor iron overload (Table
1). Instead, there was some evidence
of diminished iron stores, particularly
in males (Table 1). Similar abnormali-
ties have been observed in dEPP14 and
might result from accumulation of
protoporphyrin rather than FECH
deﬁciency.15 Five (17%) patients had
overt liver disease, suggesting that
XLPP, like autosomal recessive EPP3,4, carries a higher risk
of liver disease than dEPP. Liver disease was more common
in males (p ¼ 0.008), and one obligate carrier was asymp-
tomatic (Figure 2; family G, II4), but otherwise we found
no evidence that X inactivation led to milder disease in
females. Erythrocyte protoporphyrin concentrations in
photosensitive patients were not signiﬁcantly different be-
tween the sexes (Table 1). These data show that disruption
of the C-terminal region of ALAS2 leads to the production
of protoporphyrin in excess of the amount required for
hemoglobinization and in quantities sufﬁcient to cause
photosensitivity and liver damage, in spite of normal
FECH activity; this is a situation unique in human disease.
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Figure 3. C-Terminal Deletions in ALAS2 Cause X-Linked Dominant Protoporphyria
(A) Sequence analysis of genomic DNA from male patients showing deletions in the ALAS2 gene.
(B) Predicted effects of deletions on ALAS2 C-terminal sequences.
(C–E) Prokaryotic expression of wild-type and mutant ALAS2 enzymes: Rates of formation of ALA (C) and porphyrin (D) by bacterial
lysates; means and ranges for three experiments are shown. (E) Porphyrin fluorescence (UVA light) in bacterial pellets.To investigate the effect of the mutants on ALAS2 ac-
tivity, we expressed both mutant enzymes in Escherichia
coli. PCR-ampliﬁed cDNAs for the delAT and delAGTG
mutations were introduced into pMALc2-AE2 (ALAS2
WT)16 by site-directed mutagenesis with the Quick-
Change Site Directed Mutagenesis Kit (Stratagene, La
Jolla, CA) and the following oligonucleotides: delAT
sense 50-ACACTTTGAGCTCGAGTGAGTGGGAACG-30 and
delAGTG sense 50-CACTTTGAGCTCATGAGTGGG AACG
TTCCTACTTGC-30 and their complementary antisense
oligonucleotides. We conﬁrmed the sequences of the re-
sulting clones for the entire coding region, and we se-
quenced each mutated ALAS2 cDNA to ensure that
only the desired mutation had been introduced and
that the remainder of the sequence was correct. Expres-
sion constructs were transfected into Escherichia coli
BL21 (Invitrogen), and overnight cultures were grown
in LB (Lennox L Broth Base, Invitrogen) media with
100 mg/ml ampicillin (PANPHARMA).The next day,
20 ml cultures in LB/ampicillin media were initiated
with the overnight cultures and grown to 1.2 A600 units.
Induction with 0.1 mM isopropyl b-D-thiogalactopyrano-
side was performed in LB/ampicillin media for 4 hr at
22C. Cells were pelleted at 2500 rpm for 10 min. The
recombinant bacteria were grown, and ALAS2 activities
of controls and mutant enzymes were determined in bac-
teria lysates as previously described but with minorThe Americanmodiﬁcations.16 Enzyme activities were expressed in
pmol of 5-aminolevulinate (ALA) and porphyrin/hr/mg
protein at 37C.
These expression studies showed that both deletions
markedly increase ALAS2 activity and that some of the
ALA that is produced is further metabolised to porphyrin
(Figures 3C–3E). E. coli BL21 transformed with mutant
plasmids accumulated porphyrin (mutant, 5000 nmol/g
protein; wild-type, less than 8 nmol/g) without the addi-
tion of substrates for ALAS2. These ﬁndings of a gain of
function strongly suggest that protoporphyrin and its
zinc chelate accumulates in XLDPP because the rate of
ALA formation is increased to such an extent that insertion
of Fe2þ into PP by FECH becomes rate limiting for heme
synthesis. Gain-of-functionmutations have not previously
been identiﬁed in genes of the heme biosynthetic path-
way1 but, as in our families, characteristically cause domi-
nant disorders.
Excretion of ALA and other protoporphyrin precursors is
normal in XLDPP (data not shown), indicating thatmost of
theALAproducedby erythroid cells ismetabolized toproto-
porphyrin. Some is used for hemoglobin synthesis, but the
fate of the rest is uncertain. Because FECH activity in ery-
throid cells exceeds that required for hemoglobin synthe-
sis,2 some may be converted to free heme and exported
from the cytoplasm.17 However, the accumulation of zinc
protoporphyrin in XLDPP, indicating that FECH is usingJournal of Human Genetics 83, 408–414, September 12, 2008 411
Figure 4. Comparison of C-terminal Sequences of ALAS enzymes
(A) Alignment of ALAS C-terminal sequences.
(B) Phylogenetic tree showing relationships between ALAS genes constructed with ClustalW.its alternative metal substrate, suggests that formation of
excess heme can be prevented by lack of available iron.
The phenotype of iron deﬁciency in XLDPP (Figure 1)
closely resembles that of Ireb2/ mice, in which deletion
of iron-regulatory protein 2 (IRP2) leads to overexpression
of ALAS2, erythroblast iron deﬁciency, andmicrocytic ane-
mia.18 In the patient whose clinical course is shown in
Figure 1, iron repletion decreased protoporphyrin accumu-
lation and corrected the anemia. However, zinc protopor-
phyrin did not decrease, as it does in uncomplicated iron
deﬁciency.19 This might indicate that the synthesis of zinc
protoporphyrin becomes limited by intra-mitochondrial
availability of Zn2þwhen theprotoporphyrinpool is greatly
expanded.18 These ﬁndings are consistentwith the hypoth-
esis that the regulatory system that enables efﬁcient
utilizationof iron forhemesynthesisduringerythroiddiffer-
entiation20 allows matching of erythroblast iron uptake to
intra-mitochondrial heme synthesis to be maintained even
when excess protoporphyrin is present. The mechanism
bywhich this is achieved is unknownbutmight involve reg-
ulation of transferrin receptor-1 expression in erythroblasts
through heme-mediated degradation of IRP2.21
The 26 C-terminal amino acids of ALAS2 are highly con-
served and have diverged from ALAS1 (Figure 4), which
suggests that this sequence might have an important, but
unknown, erythroid-speciﬁc function. During erythropoi-412 The American Journal of Human Genetics 83, 408–414, Septemesis, tight coordination of substrate supply to FECH nor-
mally prevents accumulation of toxic amounts of pro-
toporphyrin. Coordination is largely achieved through
iron-dependent post-transcriptional regulation of synthe-
sis of ALAS2.2 This system fails in XLDPP because the
mutations that we have described greatly increase ALAS2
activity. A possible mechanism might be stabilization
against degradation or an intrinsic increase in speciﬁc ac-
tivity. This C-terminal sequence is not present in ALASRc,
the only ALAS for which the crystal structure has been
reported.22 Sequence similarities between ALASRc and
human ALAS222 suggest that it is not directly involved in
pyridoxal 5-phospate-dependent catalysis. Our ﬁndings
indicate that it modulates enzyme activity, but the mecha-
nism of this effect remains to be determined. The discovery
of gain-of-function mutations in ALAS2 identiﬁes a previ-
ously undeﬁned type of human porphyria, provides new
information about the regulation of substrate supply for
heme synthesis during erythroid differentiation, and iden-
tiﬁes a potential tool for increasing erythroid heme synthe-
sis in experimental systems.
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Supplemental Data include one ﬁgure, available online at http://
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